- Conditions
- Type 2 Diabetes, End Stage Renal Disease
- Interventions
- Placebo, Sitagliptin
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,671
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Interventions
- ESG + lifestyle modification, Lifestyle modification
- Device · Behavioral
- Lead sponsor
- Pichamol Jirapinyo, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Morgantown, West Virginia
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- LY3502970, Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Anaheim, California • Huntington Park, California • Los Angeles, California + 17 more
- Conditions
- Type 2 Diabetes
- Interventions
- Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
- Interventions
- Adipose tissue biopsy
- Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Diabetes
- Interventions
- EpxDiabetes software
- Behavioral
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Type 2 Diabetes (Adult Onset)
- Interventions
- Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Self-Monitoring of Behavior for Physical Activity, Action Planning for Physical Activity, Self-Monitoring of Behavior for Mood, Action Planning for Mood
- Behavioral
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 4
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- mHealth for Diabetes Adherence Support
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Pregnancy, Continuous Glucose Monitoring System
- Interventions
- Continuous glucose monitor, Glucometer
- Device
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Sewell, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Insulin Resistance, Diabetes, Obesity
- Interventions
- tauroursodeoxycholic acid, placebo, sodium phenylbutyrate
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- NAFLD, Obesity, Diabetes Mellitus, Type 2
- Interventions
- Alternate Daily Fasting (ADF), Caloric Restriction (CR)
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tesaglitazar 0.5, Insulin at least 30 units/day
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more
- Conditions
- Diabetes, Diabetes Mellitus Type 2
- Interventions
- Liraglutide, Metformin, Placebo, NNC0090-2746
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 20
- States / cities
- Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Obesity
- Interventions
- DEXCOM G6 RT-CGM
- Device
- Lead sponsor
- Nicole Ehrhardt, MD
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetic Cardiomyopathies
- Interventions
- AT-001, Placebo
- Drug
- Lead sponsor
- Applied Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 28
- States / cities
- Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
- Conditions
- HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
- Interventions
- Pioglitazone, Exercise training
- Drug · Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
- Interventions
- Sitagliptin (Januvia)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- BIOD-531, Humalog Mix 75/25, Humulin R U-500
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes
- Interventions
- HM11260C, liraglutide, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- CA, California
- Conditions
- Type 2 Diabetes
- Interventions
- Hepatic Ultrasound Insonification
- Device
- Lead sponsor
- General Electric Research
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes
- Interventions
- Biomebliss, Metformin, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland